Likewise, tumor-intrinsic BRAFi+MEKi resistance via reactivation of the MAPK/ERK pathway may lead to tumor immune exclusion via increased expression of CCND1 and subsequent CDK4/6 activation, which is associated with a tumor-intrinsic T cell exclusionary transcriptional program14. Here, CDK4 is linked to neoplasm.